Search
Displaying 511–520 of 645 for “retinal diseases”
-
Share Your Vision: Heather Edwards
Beacon StoriesHeather Edwards has turned her personal journey with cone-rod dystrophy into a mission to support others facing similar challenges. Despite facing difficulties during her youth, Heather now uses her experiences to advocate for awareness and support for blinding diseases, emphasizing that blindness is a spectrum and each person’s experience is uniquely valuable.
-
Research News
The Phase 3 trial is expected to begin in Q1 2025
-
AREDS Formula Reduces Risk of Visual Acuity Loss for People with Geographic Atrophy
Research NewsPreviously, the formula was thought to only reduce risk of early age-related macular degeneration advancing to late-stage disease
-
Eye on the Cure Podcast | Episode 69: Dr. Francois Paquet-Durand
Eye on the CureFrancois Paquet-Durand, PhD, a professor from the University of Tübingen and co-founder of the company Mireca, talks to host Ben Shaberman about the long journey of an emerging, Foundation-funded drug for the treatment of certain forms of retinitis pigmentosa. The episode highlights the challenges that scientists often encounter when developing a drug for a retinal disease, and the persistence and tenacity that are required to keep it moving forward.
-
Blind Guy Biking: Enduring the Trails for Stargardt
Beacon Stories Fundraiser Success StoriesChris Smith, a mountain bike enthusiast who was diagnosed with Stargardt disease, transformed his bike into a lifeline after losing his driver’s license. Now, 15 years later, he’s tackling the grueling 2,745-mile Tour Divide race while raising funds for the Foundation Fighting Blindness.
-
Beacon Doses First Patient in its Phase 2/3 VISTA Clinical Trial for XLRP Gene Therapy
Research NewsThe company plans to apply for regulatory approval for the gene therapy with data from VISTA and its earlier clinical trials.
-
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
Research NewsThe emerging treatment is designed to work independent of the patient’s mutated gene.
-
Research News
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO
Eye on the CureMichael Voevodsky, MBA, CEO at MitoChem Therapeutics, talks to host Ben Shaberman about his company’s emerging, gene-agnostic treatment designed to boost mitochondrial function for preserving vision in people with retinitis pigmentosa, age-related macular degeneration, and other retinal conditions.
.png)
.png)
%20(13).png)
